Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
WALTHAM, Mass., April 19, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2017 financial results will be released on Tuesday, May 2, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 3903846
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 3903846
A telephone replay will be available from approximately 11:00 a.m. ET on May 2, 2017 through midnight on May 9, 2017.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s and maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
